Advertisement
Clinical Breast Cancer Home
Advanced searchSave search
Letter to the Editor| Volume 22, ISSUE 2, e239-e241, February 2022

Download started.

Ok

Impact of Incorporating Trabecular Bone Score Into Fracture Risk Assessment and Recommendation for Use of Bone-Modifying Agents in Women With Breast Cancer

  • Mahwash F. Siddiqui
    Affiliations
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
    Search for articles by this author
  • Naim M. Maalouf
    Correspondence
    Address for correspondence: Naim M. Maalouf, MD, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas TX 75390-8885
    Affiliations
    Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

    Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX
    Search for articles by this author
Published:July 15, 2021DOI:https://doi.org/10.1016/j.clbc.2021.07.004
Impact of Incorporating Trabecular Bone Score Into Fracture Risk Assessment and Recommendation for Use of Bone-Modifying Agents in Women With Breast Cancer
Previous ArticleReview of Variables Associated With Positive Surgical Margins Using Scout Reflector Localizations for Breast Conservation Therapy
Next ArticleAGR2 and AGR3 play an important role in the clinical characterization and prognosis of basal like breast cancer
      We read with great interest the recent review article by Shapiro on the use of bone modifying agents (BMA) in patients with breast cancer.
      • Shapiro CL.
      Bone-modifying agents (BMAs) in breast cancer.
      Clin Breast Cancer. 2021; (Published online)https://doi.org/10.1016/j.clbc.2021.04.009
      The article highlights the importance of fracture risk assessment in guiding prevention and treatment of low bone mass in patients with breast cancer, and in determining the need to initiate BMAs.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Shapiro CL.
        Bone-modifying agents (BMAs) in breast cancer.
        Clin Breast Cancer. 2021; (Published online)https://doi.org/10.1016/j.clbc.2021.04.009
        View in Article
        • Gralow JR
        • Biermann JS
        • Farooki A
        • et al.
        NCCN task force report: bone health in cancer care.
        J Natl Compr Cancer Netw. 2013; 11: S-1-S-50https://doi.org/10.6004/jnccn.2013.0215
        View in Article
        • Hadji P
        • Aapro MS
        • Body JJ
        • et al.
        Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.
        J Bone Oncol. 2017; 7: 1-12https://doi.org/10.1016/j.jbo.2017.03.001
        View in Article
        • Shapiro CL
        • Lacchetti C
        • Neuner J.
        Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline summary.
        J Oncol Pract. 2019; 15: 665-669https://doi.org/10.1200/JOP.19.00427
        View in Article
        • Coleman R
        • Hadji P
        • Body JJ
        • et al.
        Bone health in cancer: ESMO clinical practice guidelines.
        Ann Oncol. 2020; 31: 1650-1663https://doi.org/10.1016/j.annonc.2020.07.019
        View in Article
        • Martineau P
        • Leslie WD.
        Trabecular bone score (TBS): Method and applications.
        Bone. 2017; 104: 66-72https://doi.org/10.1016/j.bone.2017.01.035
        View in Article
        • McCloskey EV.
        • Odén A
        • Harvey NC
        • et al.
        A Meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX.
        J Bone Miner Res. 2016; 31: 940-948https://doi.org/10.1002/jbmr.2734
        View in Article
        • DeSantis CE
        • Ma J
        • Gaudet MM
        • et al.
        Breast cancer statistics.
        CA Cancer J Clin. 2019; 69: 438-451https://doi.org/10.3322/caac.21583
        View in Article

      Article info

      Publication history

      Published online: July 15, 2021
      Accepted: July 8, 2021
      Received: July 1, 2021

      Identification

      DOI: https://doi.org/10.1016/j.clbc.2021.07.004

      Copyright

      © 2021 Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX